Group 1 - The core viewpoint of the article highlights the rapid growth of BD transactions and the continuous catalysis of innovative drugs, emphasizing the investment value of the Hang Seng Biotechnology ETF (520933) [1] - Over the past decade, the Chinese pharmaceutical industry has undergone a transformation driven by policy support, leading to industrial upgrades [1] - The implementation of the "Full Chain Support for Innovative Drug Development" plan in July 2024 marks a new phase in national support for innovative drugs, elevating their development to a strategic level [1] Group 2 - Chinese innovative drugs have gained international recognition for their innovation and value, indicating a trend towards globalization, whether through independent expansion or licensing-out models [1] - The Hang Seng Biotechnology Index focuses on innovative drugs, showcasing three main advantages: gathering leading companies, scarce futures liquidity, and high elasticity & Sharpe ratio [1] - Investors looking to conveniently participate in core leading innovative drug companies can consider the Hang Seng Biotechnology ETF (520933) for a streamlined investment approach [1]
BD交易火热，创新药持续催化，关注恒生生物科技ETF国泰（520933）投资价值
Sou Hu Cai Jing·2026-01-14 05:44